Filing Flows › Royalty Pharma (RPRX) › R&D spending
Royalty Pharma (RPRX) R&D spending by quarter
Royalty Pharma's R&D spending was $63.2M in Q3 2026 (third quarter 2026), -35% from Q2 2026. Over the last 4 quarters it ranged from $50.5M (Q4 2025) to $97.9M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $63.2M | -35% | +25% |
| Q2 2026 | $97.9M | +94% | — |
| Q4 2025 | $50.5M | 0% | — |
| Q3 2025 | $50.5M | — | — |
Q3 2026 at a glance
Royalty Pharma, Q3 2026: revenue $690M (+13% year over year), operating margin 59.5%, net earnings $145M, operating cash flow $686M. The chart follows the revenue to costs, profit and cash.
Questions
What is Royalty Pharma's R&D spending?
Royalty Pharma's R&D spending was $63.2M in Q3 2026 (third quarter 2026), -35% from Q2 2026.
How has Royalty Pharma's R&D spending changed?
Over the last 4 quarters it ranged from $50.5M (Q4 2025) to $97.9M (Q2 2026).